New RNA research approach aims to increase EHMT1 protein

A new research project is attempting to address Kleefstra syndrome as close as possible to its molecular cause: the insufficient amount of functional EHMT1 protein. The Department of Chemistry at the University of Chicago and IDefine – The Kleefstra Syndrome Foundation announced on March 30, 2026, a funded, six-month collaboration with Bryan Dickinson's laboratory.

The goal is to develop programmable RNA molecular tools which, if they work as designed, could help the cell produce more protein from its functional copy EHMT1 that it already possesses. According to the announcement, the approach does not introduce a new copy of the gene. It seeks to help the cell produce more EHMT1 protein from the RNA already produced by the functional gene.

The news concerns the launch of a research program rather than the presentation of results. No human trials have been reported, there is no patient group, and no data on efficacy, safety, dosage, or administration methods have been published. The approach is at a very early preclinical stage of technology development and does not constitute an available treatment.

What does «translation activation» mean»

In molecular biology, «translation» is not about transferring a text from one language to another. It is the process by which the cell reads a messenger RNA message and uses this information to build a protein. The programmable activation of RNA translation aims, simply put, to produce more protein from the cell's own existing RNA instructions.

In Kleefstra syndrome type 1, there is a deficiency of one functional copy of the EHMT1. This means that one copy of the gene remains functional, but it is not sufficient to produce the amount of functional protein required for normal development and function. The EHMT1 protein is an epigenetic regulator: it is involved in controlling the activation and repression of many genes, among other ways, through the methylation of histone H3 at lysine 9 (H3K9).

The basic idea of the program is therefore attractive: instead of transferring a new gene into cells, to enhance protein production from the RNA message of the functional copy already present. However, the theoretical logic of an approach is not proof that it can be applied safely to the human organism.

What does the cooperation provide for

The announcement outlines an initial six-month period for the development of the molecular tools. Testing on neurons derived from patient cells is presented as a subsequent milestone, provided the first stage is successfully completed. The development of a clinical delivery method is also scheduled for a later stage.

No measured increase in EHMT1 protein, cellular feature correction, efficacy in an animal model, or human benefit has been reported yet. There are no clinical trial participants and no trial start date has been announced. The only specific quantitative information about the project is the six-month duration of the initial collaboration.

This distinction is critical. A research program with a therapeutic orientation can be scientifically significant without constituting a therapy. Between an early molecular idea and a clinical trial, there are usually many stages: confirmation that the tool works, testing in appropriate cell models, evaluation of its tissue distribution, safety and toxicity studies, delivery development, and regulatory review.

The difficult questions of EHMT1 targeting

Increasing EHMT1 production is not necessarily a matter of simple maximization. Because EHMT1 regulates gene expression and has widespread effects, the precise amount of protein, the timing of its increase, the targeted cell type, and the distribution of the intervention in the brain and other tissues may matter.

Delivering a molecular tool to the appropriate cells of the human brain remains a distinct and demanding challenge. The announcement does not show that this obstacle has been overcome. We also do not know whether increasing EHMT1 after years of development could improve already established neurodevelopmental features, affect the risk of skill loss, or alter other manifestations of the syndrome.

Even if the technology successfully increases protein in a laboratory system, it must be proven that the increase is in an appropriate range and has a meaningful functional effect without unacceptable effects. None of these conditions have yet been documented in the announcement.